itgb6 Search Results


gene exp itgb6 cf02730239 m1  (Thermo Fisher)
90
Thermo Fisher gene exp itgb6 cf02730239 m1
Gene Exp Itgb6 Cf02730239 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp itgb6 cf02730239 m1/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
gene exp itgb6 cf02730239 m1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
integrin α5β6  (Sino Biological)
94
Sino Biological integrin α5β6
Integrin α5β6, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrin α5β6/product/Sino Biological
Average 94 stars, based on 1 article reviews
integrin α5β6 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
gene exp itgb6 hs00982345 m1  (Thermo Fisher)
85
Thermo Fisher gene exp itgb6 hs00982345 m1
Gene Exp Itgb6 Hs00982345 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp itgb6 hs00982345 m1/product/Thermo Fisher
Average 85 stars, based on 1 article reviews
gene exp itgb6 hs00982345 m1 - by Bioz Stars, 2026-03
85/100 stars
  Buy from Supplier
gene exp itgb6 hs00168458 m1  (Thermo Fisher)
86
Thermo Fisher gene exp itgb6 hs00168458 m1
Gene Exp Itgb6 Hs00168458 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp itgb6 hs00168458 m1/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
gene exp itgb6 hs00168458 m1 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
gene exp itgb6 mm01269869 m1  (Thermo Fisher)
85
Thermo Fisher gene exp itgb6 mm01269869 m1
Gene Exp Itgb6 Mm01269869 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp itgb6 mm01269869 m1/product/Thermo Fisher
Average 85 stars, based on 1 article reviews
gene exp itgb6 mm01269869 m1 - by Bioz Stars, 2026-03
85/100 stars
  Buy from Supplier
anti itgb6 polyclonal antibody  (Atlas Antibodies)
92
Atlas Antibodies anti itgb6 polyclonal antibody
Validation of <t>ITGB6</t> as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.
Anti Itgb6 Polyclonal Antibody, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti itgb6 polyclonal antibody/product/Atlas Antibodies
Average 92 stars, based on 1 article reviews
anti itgb6 polyclonal antibody - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
gene exp itgb6 hs00982346 m1  (Thermo Fisher)
86
Thermo Fisher gene exp itgb6 hs00982346 m1
Validation of <t>ITGB6</t> as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.
Gene Exp Itgb6 Hs00982346 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp itgb6 hs00982346 m1/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
gene exp itgb6 hs00982346 m1 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
mintegrin α5β6  (Sino Biological)
94
Sino Biological mintegrin α5β6
Validation of <t>ITGB6</t> as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.
Mintegrin α5β6, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mintegrin α5β6/product/Sino Biological
Average 94 stars, based on 1 article reviews
mintegrin α5β6 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
gene exp itgb6 mm00445326 m1  (Thermo Fisher)
86
Thermo Fisher gene exp itgb6 mm00445326 m1
Validation of <t>ITGB6</t> as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.
Gene Exp Itgb6 Mm00445326 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp itgb6 mm00445326 m1/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
gene exp itgb6 mm00445326 m1 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
shrna  (OriGene)
90
OriGene shrna
Validation of <t>ITGB6</t> as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.
Shrna, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shrna/product/OriGene
Average 90 stars, based on 1 article reviews
shrna - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti integrin β6  (Proteintech)
93
Proteintech anti integrin β6
Validation of <t>ITGB6</t> as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.
Anti Integrin β6, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti integrin β6/product/Proteintech
Average 93 stars, based on 1 article reviews
anti integrin β6 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Validation of ITGB6 as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.

Journal: Clinical and Translational Gastroenterology

Article Title: β 6 -Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma

doi: 10.14309/ctg.0000000000000395

Figure Lengend Snippet: Validation of ITGB6 as possible biomarker for PAC. ( a ) Serum ITGB6 levels were assessed in a prospective study cohort of 27 patients with PAC (cohort 1, N = 27). As control served 9 healthy volunteers (Ctrl; N = 9) and 10 patients with cP (N = 10). Significant differences in ITGB6 levels were observed between patients with PAC and Ctrl ( P = 0.019). ( b ) Comparing patients with or without distant metastatic PAC, serum ITGB6 levels were not significantly different. However, a significant increase in ITGB6 levels was observed between Ctrl and patients with nonmetastatic PAC ( P = 0.019). ( c ) To assess the prognostic value of serum ITGB6 levels, patients with PAC were plotted against their status of survival at time of blood assessment. A significant difference in ITGB6 concentration was observed between patients with PAC with status alive vs dead ( P = 0.007). ( d ) Two-dimensional scatterplots depict serum ITGB6 levels in relation to the serum CA19-9 levels from each cP ( r s = 0.511; P = 0.132) and patient with PAC ( r s = 0.210; P = 0.302). In ( a – c ), Mann–Whitney U Exact and Sig. 2-Tailed test were performed, and in ( d ), Spearman's rho correlation ( r s ) and Sig. 2-tailed test were performed. ( d ) Red lines indicate ITGB6 cutoff value at 0.1 ng/mL and black line CA19-9 cutoff value at 37.0 kU/L, respectively. cP, chronic pancreatitis; Ctrl, control; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; r s, Spearman's rho correlation. *Means P < 0.05.

Article Snippet: A tissue microarray (TMA) with formalin-fixed paraffin-embedded PAC tissue specimens from 83 patients was automatically stained with a human anti-ITGB6 polyclonal antibody raised in rabbit (HPA023626, dilution 1:100; Atlas Antibodies AB, Bromma, Sweden) using a validated standard protocol on a Ventana automat (Ventana Medical System, Tucson, AZ).

Techniques: Biomarker Discovery, Control, Concentration Assay, MANN-WHITNEY

Serum ITGB6 levels may predict overall and progression-free survival in patients with PAC. ( a ) Survival rates and ( b ) progression-free survival of patients with PAC who underwent systemic therapy are plotted according to serum ITGB6 changes after initiation (N = 24; cohort 2). ( c ) Two-dimensional scatterplots depict lymph node ratio (LNR) in relation to exits after surgery (months) for each patient in accordance to the ITGB6 protein expression pattern. Hazard ratio (HR) was calculated with the Cox regression. ( d ) Overall survival in AU12 patients with PAC (N582; cohort 3) was plotted according to ITGB6 protein expression pattern. Kaplan-Meier estimation was performed and plotted accordingly. The log-rank P values are indicated. ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma.

Journal: Clinical and Translational Gastroenterology

Article Title: β 6 -Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma

doi: 10.14309/ctg.0000000000000395

Figure Lengend Snippet: Serum ITGB6 levels may predict overall and progression-free survival in patients with PAC. ( a ) Survival rates and ( b ) progression-free survival of patients with PAC who underwent systemic therapy are plotted according to serum ITGB6 changes after initiation (N = 24; cohort 2). ( c ) Two-dimensional scatterplots depict lymph node ratio (LNR) in relation to exits after surgery (months) for each patient in accordance to the ITGB6 protein expression pattern. Hazard ratio (HR) was calculated with the Cox regression. ( d ) Overall survival in AU12 patients with PAC (N582; cohort 3) was plotted according to ITGB6 protein expression pattern. Kaplan-Meier estimation was performed and plotted accordingly. The log-rank P values are indicated. ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma.

Article Snippet: A tissue microarray (TMA) with formalin-fixed paraffin-embedded PAC tissue specimens from 83 patients was automatically stained with a human anti-ITGB6 polyclonal antibody raised in rabbit (HPA023626, dilution 1:100; Atlas Antibodies AB, Bromma, Sweden) using a validated standard protocol on a Ventana automat (Ventana Medical System, Tucson, AZ).

Techniques: Expressing

ITGB6 protein expression in PAC tissue specimens by IHC. Representative TMA specimens (from cohort 3, N = 83) illustrate ITGB6-negative (no [0] or mild [1+] expression) and ITGB6-positive PAC specimens (moderate [2+] or strong [3+] expression; scale bars: upper panel 200 μm; lower panel 100 μm). IHC, immunohistochemistry; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; TMA, tissue microarray.

Journal: Clinical and Translational Gastroenterology

Article Title: β 6 -Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma

doi: 10.14309/ctg.0000000000000395

Figure Lengend Snippet: ITGB6 protein expression in PAC tissue specimens by IHC. Representative TMA specimens (from cohort 3, N = 83) illustrate ITGB6-negative (no [0] or mild [1+] expression) and ITGB6-positive PAC specimens (moderate [2+] or strong [3+] expression; scale bars: upper panel 200 μm; lower panel 100 μm). IHC, immunohistochemistry; ITGB6, β 6 -integrin; PAC, pancreatic adenocarcinoma; TMA, tissue microarray.

Article Snippet: A tissue microarray (TMA) with formalin-fixed paraffin-embedded PAC tissue specimens from 83 patients was automatically stained with a human anti-ITGB6 polyclonal antibody raised in rabbit (HPA023626, dilution 1:100; Atlas Antibodies AB, Bromma, Sweden) using a validated standard protocol on a Ventana automat (Ventana Medical System, Tucson, AZ).

Techniques: Expressing, Immunohistochemistry, Microarray